• 1
    Wong F, Villamil A, Merli M, Romero G, Angeli P, Caraceni P, et al. Prevalence of diastolic dysfunction in cirrhosis, and its clinical significance [abstract]. Hepatology 2011;54(suppl 1):475A.
  • 2
    Torregrosa M, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005;42:68-74.
  • 3
    Sampathkumar P, Lerman A, Kim BY, Narr BJ, Poterucha JJ, Torsher LC, Plevak DJ. Post-liver transplantation myocardial dysfunction. Liver Transpl Surg 1998;4:399-403.
  • 4
    Stewart KS, Rhim CH, Bahrain ML, Ashkezari ZD, Ozdemirli M, Fishbein TM, et al. Nonischemic cardiomyopathy after orthotopic liver transplantation: a report of three cases and a review of the literature. Liver Transpl 2005;11:573-578.
  • 5
    Schnell F, Donal E, Lorho R, Lavoué S, Gacouin A, Compagnon P, et al. Severe left-sided heart failure early after liver transplantation. Liver Transpl 2009;15:1296-1305.
  • 6
    Dowsley TF, Bayne DB, Langnas AN, Dumitru I, Windle JR, Porter TR, Raichlin E. Diastolic dysfunction in patients with end-stage liver disease is associated with development of heart failure early after liver transplantation. Transplantation 2012;94:646-651.
  • 7
    Rayes N, Bechstein WO, Keck H, Blumhardt G, Lohmann R, Neuhaus P. Cause of death after liver transplantation: an analysis of 41 cases in 382 patients [in German]. Zentralbl Chir 1995;120:435-438.
  • 8
    Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 2003;38:461-467.
  • 9
    Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004;10:1441-1453.
  • 10
    Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000;6(suppl 1):S44-S52.
  • 11
    Parekh J, Corley DA, Feng S. Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation. Am J Transplant 2012;12:2181-2187.
  • 12
    Dec GW, Kondo N, Farrell ML, Dienstag J, Cosimi AB, Semigran MJ. Cardiovascular complications following liver transplantation. Clin Transplant 1995;9:463-471.
  • 13
    Ikegami T, Shirabe K, Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, et al. The impact of renal replacement therapy before or after living donor liver transplantation. Clin Transplant 2012;26:143-148.
  • 14
    Ganda A, Weiner SD, Chudasama NL, Valeri AM, Jadoon A, Shimbo D, Radhakrishnan J. Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction. Clin Nephrol 2012;77:366-375.
  • 15
    Chen CY, Yoshida A, Asakura M, Hasegawa T, Takahama H, Amaki M, et al. Serum blood urea nitrogen and plasma brain natriuretic peptide and low diastolic blood pressure predict cardiovascular morbidity and mortality following discharge in acute decompensated heart failure patients. Circ J 2012;76:2372-2379.
  • 16
    Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010;53:179-190.
  • 17
    Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953;32:1025-1033.
  • 18
    Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34.
  • 19
    Day CP, James OF, Butler TJ, Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet 1993;341:1423-1428.
  • 20
    Lazzeri C, La Villa G, Laffi G, Vecchiarino S, Gambilonghi F, Gentilini P, Franchi F. Autonomic regulation of heart rate and QT interval in nonalcoholic cirrhosis with ascites. Digestion 1997;58:580-586.
  • 21
    Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996;23:1128-1134.
  • 22
    Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol 2004;40:239-246.
  • 23
    Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci E, et al. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol 2008;48:415-421.
  • 24
    Martínez-Palli G, Taurà P, Balust J, Beltrán J, Zavala E, Garcia-Valdecasas JC. Liver transplantation in high-risk patients: hepatopulmonary syndrome and portopulmonary hypertension. Transplant Proc 2005;37:3861-3864.
  • 25
    Porres-Aguilar M, Zuckerman MJ, Figueroa-Casas JB, Krowka MJ. Portopulmonary hypertension: state of the art. Ann Hepatol 2008;7:321-330.
  • 26
    Hemnes AR, Robbins IM. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl 2009;15:15-19.
  • 27
    Melgosa MT, Ricci GL, García-Pagan JC, Blanco I, Escribano P, Abraldes JG, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl 2010;16:348-356.
  • 28
    Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996;24:451-459.
  • 29
    Raizada V, Skipper B, Luo W, Griffith J. Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects. J Investig Med 2007;55:341-359.
  • 30
    Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transpl 2002;8:690-700.
  • 31
    Papastergiou V, Skorda L, Lisgos P, Papakonstantinou N, Giakoumakis T, Ntousikos K, Karatapanis S. Ultrasonographic prevalence and factors predicting left ventricular diastolic dysfunction in patients with liver cirrhosis: is there a correlation between the grade of diastolic dysfunction and the grade of liver disease? Scientific World Journal 2012;2012:615057.
  • 32
    Saito I, Saruta T, Eguchi T, Nakamura R, Kondo K, Iyori S, Kato E. Role of renin-angiotensin system in the controls of blood pressure and aldosterone in patients with cirrhosis and ascites. Jpn Heart J 1978;19:741-747.
  • 33
    Aliaga L, Zozoya JM, Omar M, Mediavilla JD, Prieto J. Interrelationships between systemic hemodynamics, urinary sodium excretion, and renin-angiotensin system in cirrhosis. Acta Gastroenterol Belg 1995;58:213-221.
  • 34
    Bauersachs J. Aldosterone antagonism in heart failure: improvement of cardiac remodelling, endothelial dysfunction and platelet activation. Eur J Clin Invest 2004;34:649-652.
  • 35
    Tuncay E, Zeydanli EN, Turan B. Cardioprotective effect of propranolol on diabetes-induced altered intracellular Ca2+ signaling in rat. J Bioenerg Biomembr 2011;43:747-756.
  • 36
    Sersté T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017-1022.
  • 37
    Tate CW III, Robertson AD, Zolty R, Shakar SF, Lindenfeld J, Wolfel EE, et al. Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). J Card Fail 2007;13:732-737.
  • 38
    Kim YK, Hwang GS, Shin WJ, Bang JY, Cho SK, Han SM. Effect of propranolol on the relationship between QT interval and vagal modulation of heart rate variability in cirrhotic patients awaiting liver transplantation. Transplant Proc 2011;43:1654-1659.
  • 39
    Siedlecki A, Foushee M, Curtis JJ, Gaston RS, Perry G, Iskandrian AE, de Mattos AM. The impact of left ventricular systolic dysfunction on survival after renal transplantation. Transplantation 2007;84:1610-1617.
  • 40
    Squadrito F, Altavilla D, Squadrito G, Saitta A, Deodato B, Arlotta M, et al. Tacrolimus limits polymorphonuclear leucocyte accumulation and protects against myocardial ischaemia-reperfusion injury. J Mol Cell Cardiol 2000;32:429-440.
  • 41
    Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005;5:2236-2243.
  • 42
    Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 2004;4:1514-1522.
  • 43
    Glassberg H. Statins in the prevention of heart failure after myocardial infarction. Curr Heart Fail Rep 2009;6:215-219.
  • 44
    Liu T, Gao Y, Gao YL, Cheng YT, Wang S, Li ZZ, et al. Tacrolimus-related hypertrophic cardiomyopathy in an adult cardiac transplant patient. Chin Med J (Engl) 2012;125:1352-1354.
  • 45
    Dehghani SM, Haghighat M, Imanieh MH, Zahmatkeshan M, Borzooei M, Amoozegar H, et al. Tacrolimus related hypertrophic cardiomyopathy in liver transplant recipients. Arch Iran Med 2010;13:116-119.